Works in Cancer Chemotherapy & Pharmacology, 2023, Vol 92, Issue 2

Results: 8

A case report of typhlitis during novel use of ropidoxuridine–capecitabine–radiotherapy for treatment-naïve rectal cancer.
Published in:
2023
By:
- Kunos, Charles A.;
- Piekarz, Richard;
- Collins, Jerry M.;
- Kinsella, Timothy J.
Publication type:
Case Study
Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study.
Published in:
Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 2, p. 141, doi. 10.1007/s00280-023-04555-2
By:
- Någård, Mats;
- Ah-See, Mei-Lin;
- Strauss, James;
- Wise-Draper, Trisha;
- Safran, Howard P.;
- Nadeau, Laura;
- Edenfield, William J.;
- Lewis, Lionel D.;
- Rekić, Dinko;
- Dota, Corina;
- Ottesen, Lone H.;
- Li, Yan;
- Mugundu, Ganesh M.
Publication type:
Article
The role of alternative splicing in lung cancer.
Published in:
Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 2, p. 83, doi. 10.1007/s00280-023-04553-4
By:
- Ning, Xuelian;
- Fu, Zitong;
- Zhang, Jing;
- Gao, Shuangshu;
- Cui, Zihan;
- Cong, Mingqi;
- Guo, Qingyu;
- Sun, Xixi;
- Li, Jing;
- Zhang, Minghui;
- Wang, Shuoshuo
Publication type:
Article
Influence of age on pharmacokinetics of capecitabine and its metabolites in older adults with cancer: a pilot study.
Published in:
Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 2, p. 135, doi. 10.1007/s00280-023-04552-5
By:
- Shafiei, Mohsen;
- Galettis, Peter;
- Beale, Philip;
- Reuter, Stephanie E.;
- Martin, Jennifer H.;
- McLachlan, Andrew J.;
- Blinman, Prunella
Publication type:
Article
Pharmacology and pharmacokinetics of elacestrant.
Published in:
Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 2, p. 157, doi. 10.1007/s00280-023-04550-7
By:
- Beumer, Jan H.;
- Foldi, Julia
Publication type:
Article
Osthole inhibits malignant phenotypes and induces ferroptosis in KRAS-mutant colorectal cancer cells via suppressing AMPK/Akt signaling.
Published in:
Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 2, p. 119, doi. 10.1007/s00280-023-04549-0
By:
- Zhou, Xinghua;
- Kang, Jian;
- Zhang, Liangliang;
- Cheng, Yue
Publication type:
Article
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.
Published in:
Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 2, p. 107, doi. 10.1007/s00280-023-04545-4
By:
- Piha-Paul, Sarina A.;
- Tseng, Chieh;
- Tran, Hai T.;
- Gao, Meng;
- Karp, Daniel D.;
- Subbiah, Vivek;
- Tsimberidou, Apostolia Maria;
- Kawedia, Jitesh D.;
- Fu, Siqing;
- Pant, Shubham;
- Yap, Timothy A.;
- Morris, Van K.;
- Kee, Bryan K.;
- Blum Murphy, Mariela;
- Lim, JoAnn;
- Meric-Bernstam, Funda
Publication type:
Article
Phase I trial of intravenous fenretinide (4-HPR) plus safingol in advanced malignancies.
Published in:
Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 2, p. 97, doi. 10.1007/s00280-023-04543-6
By:
- Boulter, Alexis C.;
- Maurer, Barry J.;
- Pogue, Meredith;
- Kang, Min H.;
- Cho, Hwangeui;
- Knight, Amanda;
- Reynolds, C. Patrick;
- Quick, Donald;
- Awasthi, Sanjay;
- Gerber, David E.
Publication type:
Article